Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Glycemic variability (GV) may be linked to the development of diabetic complications by inducing inflammation, oxidative stress, and endothelial dysfunction. Flash glucose monitoring (FGM) provides a novel method of continuously monitoring interstitial glucose levels for up to 14 days. This study randomly assigned poorly controlled type 2 diabetes mellitus patients treated with metformin and multiple daily injections of insulin (n=60) to either continuous subcutaneous insulin infusion (CSII) treatment or CSII in combination with liraglutide (CSII+Lira) treatment for 14 days during hospitalization. GV was assessed using a FGM system; weight and cardiometabolic biomarkers were also evaluated. The coefficient of variation was significantly reduced in the CSII+Lira group (P<0.001), while no significant change was observed in the CSII group. The changes differed significantly between the two groups in mean amplitude of glycemic excursions (P=0.004), standard deviation (P=0.006), and the percentage of time in the target range (4-10 mmol/L, P=0.005 and >10 mmol/L, P=0.028). The changes in mean of daily differences, interquartile range, and percentage of time in hypoglycemia (<3.3 mmol/L) and hyperglycemia (>13.9 mmol/L) identified by FGM showed no difference. Treatment with liraglutide increased serum adiponectin [33.5 (3.5, 47.7) pg/mL, P=0.003] and heme oxygenase-1 levels [0.4 (-0.0, 1.8) ng/mL, P=0.001] and reduced serum leptin levels [-2.8 (3.9) pg/mL, P<0.001]. Adding the glucagon-like peptide-1 analog liraglutide improved GV, weight, and some cardiometabolic risk markers. The FGM system is, therefore, shown to be a novel and useful method for glucose monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“In recent years, the effects of antidiabetic drugs on cardiometabolic risk factors have gained increasing attention (28).”
BackgroundContinuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0199 · Cited by 363 · cited 1×
“Previous studies have reported that glycemic fluctuation was associated with both macro- and microvascular events (20).”
BackgroundHendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Rizzo, M., Abate, N., Chandalia, M., Rizvi, A. A., Giglio, R. V., Nikolic, D., Marino Gammazza, A., Barbagallo, I., Isenovic, E. R., Banach, M., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2291 · Cited by 113 · cited 8×
“Oeseburg H. et al (32) revealed that GLP-1 can induce the expression of oxidative defense genes HO-1 and NQO1 in endothelial cells.”
BackgroundInfluentialBedenis, R., Price, A. H., Robertson, C. M., Morling, J. R., Frier, B. M., Strachan, M. W. J., & Price, J. F. (2014) · Diabetes Care · doi:10.2337/dc14-0908 · Cited by 87 · cited 1×
“Furthermore, GV is associated with both microvascular and macrovascular endpoints in type 2 diabetes (11).”
BackgroundChiefari, E., Capula, C., Vero, A., Oliverio, R., Puccio, L., Liguori, R., Pullano, V., Greco, M., Foti, D., Tirinato, D., et al. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0412 · Cited by 22
Research works printed but not linked: 24
- Dandona P, 2009, Insulin as an anti-inflammatory and antiatherogenic modulator, J Am Coll Cardiol, 53, S14, 10.1016/j.jacc.2008.10.038 · DOI · Paper page
- 1998, UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837
- Holman RR, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470 · DOI · Paper page
- Zhang S, 2012, Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats, Eur J Pharmacol, 692, 78, 10.1016/j.ejphar.2012.05.017 · DOI
- Kramer CK, 2013, Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis, Lancet Diabetes Endocrinol, 1, 28, 10.1016/S2213-8587(13)70006-8 · DOI · Paper page
- Lee MK, 2017, Impact of initial active engagement in self-monitoring with a telemonitoring device on glycemic control among patients with type 2 diabetes, Sci Rep, 7, 3866, 10.1038/s41598-017-03842-2 · DOI
- Thompson B, 2018, An overview of safety issues on use of insulin pumps and continuous glucose monitoring systems in the hospital, Curr Diab Rep, 18, 81, 10.1007/s11892-018-1056-7 · DOI
- Gerstein HC, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
- Duckworth W, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431 · DOI · Paper page
- Monnier L, 2006, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, JAMA, 295, 1681, 10.1001/jama.295.14.1681 · DOI · Paper page
- Sato T, 2019, Accuracy of flash glucose monitoring in insulin-treated patients with type 2 diabetes, J Diabetes Investig, 10, 846, 10.1111/jdi.12954 · DOI
- Maiorino MI, 2018, The effects of subcutaneous insulin infusion versus multiple insulin injections on glucose variability in young adults with type 1 diabetes: the 2-year follow-up of the observational METRO study, Diabetes Technol Ther, 20, 117, 10.1089/dia.2017.0334 · DOI
- Ajjan RA, 2019, Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system, Diab Vasc Dis Res, 16, 3, 10.1177/1479164118795252 · DOI
- Reddy M, 2018, Switching from flash glucose monitoring to continuous glucose monitoring on hypoglycemia in adults with type 1 diabetes at high hypoglycemia risk: the extension phase of the I HART CGM study, Diabetes Technol Ther, 20, 751, 10.1089/dia.2018.0252 · DOI · Paper page
- Zhou BF, 2002, Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - study on optimal cut-off points of body mass index and waist circumference in Chinese adults, Biomed Environ Sci, 15, 83
- Costantino S, 2017, Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels, Diabetes, 66, 2472, 10.2337/db17-0294 · DOI · Paper page
- Ajjan RA, 2017, How can we realize the clinical benefits of continuous glucose monitoring?, Diabetes Technol Ther, 19, S27, 10.1089/dia.2017.0021 · DOI · Paper page
- Lane W, 2014, The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial, Diabetes Obes Metab, 16, 827, 10.1111/dom.12286 · DOI · Paper page
- Pokala N, 2017, The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin, Diabetes Obes Metab, 19, 1454, 10.1111/dom.12939 · doi:10.1111/dom.12939
- Farr OM, 2016, Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study, Metabolism, 65, 945, 10.1016/j.metabol.2016.03.009 · DOI · Paper page
- Li D, 2015, Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes, Diabetes Res Clin Pract, 110, 224, 10.1016/j.diabres.2015.05.051 · DOI
- Kim Chung le T, 2009, Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression, Biochem Biophys Res Commun, 390, 613, 10.1016/j.bbrc.2009.10.015 · DOI · Paper page
- Oeseburg H, 2010, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A, Arterioscler Thromb Vasc Biol, 30, 1407, 10.1161/ATVBAHA.110.206425 · DOI · Paper page
- Sen Z, 2019, Coumarin glycosides from Hydrangea paniculata slow down the progression of diabetic nephropathy by targeting Nrf2 anti-oxidation and smad2/3-mediated profibrosis, Phytomedicine, 57, 385, 10.1016/j.phymed.2018.12.045 · doi:10.1016/j.phymed.2018.12.045
Cited by
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026) · PeerJ · doi:10.7717/peerj.20710 · Cited by 6
“…et al. (2017) ; Shao et al. (2024) ; Shi et al. (2017) ; Wu et al. (2011) ; Gurkan et al. (2014) ; Ahmad et al. (2021) ; Derosa et al. (2011) ; Luna-Marco et al. (2023) ; Zhang et al. (2018) ; Lin et al. (2022) ; Yao et al. (2020) ; Wang et al. (2019) ; Bouchi et al. (2017) ; Ripa et al. (2021) .”
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Metadata
- Authors
- Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K.
- Venue
- Brazilian Journal of Medical and Biological Research
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2020-01
- Volume
- 53
- Issue
- 1
- Pages
- e8652-e8652
- ISSN
- 0100-879X (ISSN-L)
- 1414-431X
- OpenAlex
- W2994638108
- Cited by
- 13
- References
- 10
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. https://app.cochat.ai/papers/10.1590/1414-431x20198652
- The paper
- Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K. (2020). Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/1414-431x20198652
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.